30 results about "Cardiac ischaemia" patented technology

The invention discloses a preparation method of agilawood health-care wine, which comprises the following steps: 1) raw material preparation; 2) infusion; 3) finished product preparation, that is, filtering and checking infused liquid, then bottling and sealing to prepare the agilawood health-care wine. The invention also discloses agilawood wine prepared by the method. The method provided by the invention is simple in preparation process, easy to realize, high in production efficiency, and capable of rapidly preparing agilawood health-care wine with good health-care effect. The agilawood wine provided in the invention is simple in raw material components, and reasonable in combination, and gives full and effective play to pharmacological effects of agilawood, which means that fragrance and pharmacological components of agilawood are effectively diffused into the wine; the wine has the efficacy of inhibiting mycobacterium tuberculosis, organizing central nervous system, calming, relieving cough, reducing high blood pressure, and resisting heart ischemia, and thus has the effect of health care.

A patient monitor for determining a probability that a patient has acute cardiac ischemia including an input device connectable to a patient to acquire electrocardiogram (ECG) signals from the patient, an instrumentation amplifier connected to the input terminal to combine the signals and to generate at least one ECG lead, and an analysis module. The analysis module is operable to continuously read the ECG lead, to analyze a portion of the ECG lead for a period of time, and to calculate a probability that the patient has acute cardiac ischemia based at least in part on the analyzed portion of the ECG lead.

Techniques are provided for detecting and distinguishing stroke and cardiac ischemia within a patient using an implantable medical device. In one example, a preliminary indication of stroke is detected by a pacemaker or similar implantable device based on an analysis of features of an intracardiac electrogram (IEGM) sensed by the device. Exemplary IEGM features indicative of possible stroke include the onset of prominent U-waves, the onset of notched T-waves, and changes in ST segment duration or QT duration. Upon detection of a possible stroke, the device then detects one or more hemodynamic parameters that are typically affected by cardiac ischemia. Such hemodynamic parameters can include, e.g., cardiac contractility or stroke volume. The device then distinguishes stroke and cardiac ischemia from one another based on whether any changes detected in the hemodynamic parameters are consistent with cardiac ischemia. Implantable systems that exploit subcutaneous electrocardiograms (ECGs) rather than IEGMs are also described.

The present invention relates to a real-time biosignal measurement apparatus for cardiac ischemia and reperfusion. The apparatus includes: a peristaltic pump which pumps perfusate from a tank storing the perfusate; a pressure trap which offsets the pulsation of both sides between a solution chamber temporarily storing the pumped perfusate and the perfusate tank; a heat exchanger to which the temporarily stored perfusate is applied and which transfers the heat of the perfusate; a bubble trap to which the heat transferred perfusate is applied on one side and which filters the heat transferred perfusate to transduce the perfusate to an isolated heart connected to the other side; a sensor unit which detects the gas concentration value in the myocardium of the isolated heart in real time during the cardiac ischemia reperfusion; and a control unit which is supplied with the gas concentration value in the myocardium of the isolated heart in order to analyze its correlation with the degree of a myocardial injury of the isolated heart.

Techniques are provided for use in a pacemaker or implantable cardioverter/defibrillator (ICD) for distinguishing cardiac ischemia from other conditions affecting the morphology of electrical cardiac signals sensed within a patient, such as hypoglycemia, hyperglycemia or other systemic conditions. In one example, the device detects changes in morphological features of cardiac signals indicative of possible cardiac ischemia within the patient, such as changes in ST segment elevation within an intracardiac electrogram (IEGM). The device determines whether the changes in the morphological features are the result of spatially localized changes within a portion of the heart and then distinguishes cardiac ischemia from other conditions affecting the morphology of electrical cardiac signals based on that determination. In another example, the device exploits the interval between the peak of a T-wave (Tmax) and the end of the T-wave (Tend). A significant increase in the Tend−Tmax interval is indicative of ischemia rather than a systemic condition.

The invention relates to application of nicotinamide adenine dinucleotide as an active ingredient in preparation of a drug for preventing or treating heart ischemic injuries. In experiments, caudal vein normal saline injection and a heart ischemia operation are carried out on rats in a control group, it is found through research results that a great number of apoptosis signals (TUNEL positive signals) appear on the hearts, while apoptosis signals of rats, on which caudal vein NAD+solution injection is carried out, in an experiment group can be effectively reduced.

The invention relates to a method and a post-operative care unit for analysing and quantifying an ultrasound tissue Doppler imaging (TDI) signal from a transducer fastened on the myocardium to obtain a parameter indicating regional cardiac ischaemia or correlates with global hypokinetic heart function. This has the advantage over manually operated probes that it can be automated and used continuously over long time. According to the method, a TDI signal trace corresponding to at least one of tissue velocity, strain or strain rate is extracted and correlated with an electrocardiogram to define subsections within a cardiac cycle in the extracted trace corresponding to the early systolic phase and the post-systolic phase. Then, a velocity, strain or strain rate is read in at least the post-systolic phase of the extracted trace, and a parameter which is a function of one of these readings and which indicates ischaemia or global hypokinetic function is generated.

Techniques are provided for detecting and distinguishing stroke and cardiac ischemia based on electrocardiac signals. In one example, the device senses atrial and ventricular signals within the patient along a set of unipolar sensing vectors and identifies certain morphological features within the signals such as PR intervals, ST intervals, QT intervals, T-waves, etc. The device detects changes, if any, within the morphological features such as significant shifts in ST interval elevation or an inversion in T-wave shape, which are indicative of stroke or cardiac ischemia. By selectively comparing changes detected along different unipolar sensing vectors, the device distinguishes or discriminates stroke from cardiac ischemia within the patient. The discrimination may be corroborated using various physiological and hemodynamic parameters. In some examples, the device further identifies the location of the ischemia within the heart. In still other examples, the device detects cardiac ischemia occurring during stroke.

The invention relates to uses of kappa-conotoxin PVIIA (κ-PVIIA), analogs and derivatives for activating ATP-sensitive K⁺ channels. The activation of ATP-sensitive K⁺ channels is useful for opening K_ATP channels which can be used to treat a wide range of disease and injury states, including cerebral and cardiac ischemia and asthma.

The invention discloses an application of Redesivir (Redesivir) in a medicine for preventing and treating reperfusion injury, especially heart reperfusion injury. The invention verifies the great potential of the ridecavir as the medicine for preventing and treating the heart ischemia reperfusion injury, discloses a good protection curative effect of the ridecavir on the heart ischemia reperfusion injury for the first time, provides an effective novel potential alternative medicine for clinical prevention and treatment of the reperfusion injury, expands the adaptation of the ridecavir, and has a good application prospect in prevention and treatment of the heart ischemia reperfusion injury. The application potential and the market prospect of the ridecevir are greatly improved.

The invention relates to the field of medical technology and discloses a traditional Chinese medicine composition and a preparation method thereof. The traditional Chinese medicine composition comprises main ingredients and accessories and is used for treating coronary heart disease or coronary heart disease with cardiac insufficiency, wherein the main ingredients include 2-4 parts of antler powder and 30-35 parts of radix astragali both by weight. In the implementation way of the invention, the antler powder can improve the immune function and energy metabolism of the body and increase the heart beat output; the radix astragali has the functions of positive inotropic action, improvement of diastole and systole and the like, and can improve the blood pumping function of the heart of a cardiac failure patient so as to increase the cardiac ejection fraction; the coronary blood flow is increased to relieve the heart ischemia; and the content of oxygen radicals in cardiac muscle and the like can be reduced. Therefore, the traditional Chinese medicine composition realizes treatment of the coronary heart disease or the coronary heart disease with cardiac insufficiency, is convenient to take and low in price, and avoids toxic and side effects.

Disclosed are deuterated analogs of SBT-20 and elamipretide (MTP-131). The compounds are useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.

The present invention discloses applications of vitamin E in preparation of drugs for prevention and treatment of ischemia-reperfusion-induced arrhythmia, and belongs to the pharmaceutical field. According to the present invention, the results show that vitamin E has the anti-ischemia-reperfusion-induced arrhythmia effect; with the application of the vitamin E in preparation of drugs for prevention and treatment of heart ischemia reperfusion QT interval prolongation and associated arrhythmia, the action target point of the drug is clear, and the drug is the novel ischemia reperfusion QT interval prolongation prevention and treatment drug having the known molecular structure; and through the in vitro heart ischemia reperfusion model, the results prove that the drug can reduce the QT interval prolongation caused by ischemia-reperfusion so as to reduce the related arrhythmia risk.